Overview

c-Met Second-Line Hepatocellular Carcinoma

Status:
Completed

Trial end date:
2018-02-14

Target enrollment:

Participant gender:

Summary

This is a Phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (PK) of MSC2156119J as monotherapy in subjects with MET+ advanced hepatocellular carcinoma (HCC) with child Pugh Class A liver function who have failed sorafenib treatment.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Merck KGaA
Merck KGaA, Darmstadt, Germany

Treatments:

Sorafenib
Tepotinib